On November 29, 2018 OncoSec Medical Incorporated (OncoSec) (NASDAQ: ONCS), a company developing intratumoral cancer immunotherapies, reported the presentation of new data from the company’s Phase 2 study of TAVO (tavokinogene telseplasmid) for the treatment of metastatic melanoma (Press release, OncoSec Medical, NOV 29, 2018, View Source [SID1234531716]). The newly presented data reports abscopal responses with TAVO monotherapy, finding that treatment with TAVO monotherapy resulted in 47 percent of patients experiencing tumor regression in at least one untreated lesion. These data were selected for an oral presentation at Melanoma Bridge 2018, taking place November 30 to December 1, Naples, Italy.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
"These findings are significant because they clearly demonstrate that intratumoral treatment with TAVO is having a systemic effect that goes beyond the treated tumor, and to see that effect in nearly half of treated patients is remarkable, particularly with such a well-tolerated therapy," said Alain Algazi, M.D., Lead Trial Investigator, Associate Professor, Department of Medicine (Hematology/Oncology), at the University of California San Francisco (UCSF) Helen Diller Family Comprehensive Cancer Center and Strategic Clinical Advisor to OncoSec. "These findings build upon our previous report from this study showing an approximate 30 percent overall response rate with monotherapy TAVO and further support the potential value of TAVO therapy for this patient population."
OMS-100 is a Phase 2 study of monotherapy TAVO for the treatment of patients with metastatic melanoma. In all, 51 subjects were enrolled in three treatment arms. Reponses data from the study were previously reported, with approximately 30 percent of subjects achieving a best overall response based on RECIST criteria. In addition, 47 percent of patients had stable disease, resulting in a DCR (Disease Control Rate) of 77 percent. Among patients who responded to monotherapy, investigators noted upregulation of innate immune mediators in the periphery of responding patients after treatment. TAVO was well tolerated, with predominantly grade 1 procedural related adverse events.
Slides from the Melanoma Bridge will be available following the conference on www.oncosec.com